Lipika Goyal is an Assistant Professor of Medicine at Harvard Medical School and a member of the faculty in Gastrointestinal Medical Oncology at the Massachusetts General Hospital Cancer Center. She completed her undergraduate degree in neuroscience at the University of Pennsylvania and then received a Rhodes Scholarship to pursue a Master of Philosophy in Development Studies at the University of Oxford. She completed her medical degree from Harvard Medical School and then went on to do her residency from the Brigham and Woman’s Hospital and her hematology/oncology fellowship at the Dana Farber/Harvard Cancer Center. She currently leads the Liver Cancer Research Program at MGH, and her research focuses on the development of effective therapies for cholangiocarcinoma and hepatocellular carcinoma. Dr. Goyal has been recognized for her work in understanding clinically acquired FGFR resistance in patients with FGFR2 fusion positive cholangiocarcinoma and identifying sequential strategies of FGFR inhibitors to prolong clinical benefit in these patients. As a clinical trialist and translational scientist, she is the principal investigator of multiple clinical trials and works on drug resistance, biomarker discovery, and immunotherapy in hepatobiliary cancers. She serves on the Steering Committee for NCI Liver Cancer Moonshot Program, and her research is supported by American Cancer Society Clinical Scientist Development Grant, the Department of Defense, the NIH GI SPORE Award, and the Cholangiocarcinoma Foundation Andrea Marie Fuquay Research Fellowship.